Get started
Author

Philippe Ronchin

Observed names: P Ronchin, P. Ronchin, Philippe RONCHIN, R. Philippe, Ronchin, P.
ORCID: 0009-0002-1476-2447
Observed ORCID: 0009-0002-1476-2447
OpenAlex ID: A5089019258
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
2021 · Thierry Conroy, Jean-François Bosset, et al. · The Lancet Oncology · 1,428
PDF
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
2022 · Karim Fizazi, Stéphanie Foulon, et al. · The Lancet · 888
PDF
Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer
2004 · E. Guardiola, F. Peyrade, et al. · European Journal of Cancer · 119
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
2024 · Alberto Bossi, Stéphanie Foulon, et al. · The Lancet · 112
Anal Canal Cancer: Management of Inguinal Nodes and Benefit of Prophylactic Inguinal Irradiation (CORS-03 Study)
2011 · Cécile Ortholan, Michel Resbeut, et al. · International Journal of Radiation Oncology*Biology*Physics · 85
Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.
2023 · Alberto Bossi, Stéphanie Foulon, et al. · Journal of Clinical Oncology · 59
PDF
LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1
2021 · K. Fizazi, J. Carles Galceran, et al. · Annals of Oncology · 52
Exclusive Chemoradiotherapy With or Without Radiation Dose Escalation in Esophageal Cancer: Multicenter Phase 2/3 Randomized Trial CONCORDE (PRODIGE-26)
2021 · G. Crehange, C. M'vondo, et al. · International Journal of Radiation Oncology*Biology*Physics · 46
Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study
1996 · M. Sanson, A. Ameri, et al. · European Journal of Cancer · 46
A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
2021 · Karim Fizazi, Xavier Maldonado, et al. · Journal of Clinical Oncology · 44
High-Dose Split-Course Radiation Therapy for Anal Cancer: Outcome Analysis Regarding the Boost Strategy (CORS-03 Study)
2010 · Jean-Michel Hannoun-Levi, Cécile Ortholan, et al. · International Journal of Radiation Oncology*Biology*Physics · 43
Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial.
2024 · Christophe Hennequin, Paul Sargos, et al. · Journal of Clinical Oncology · 39
PDF
A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer
2004 · J.M. Ferrero, C. Foa, et al. · Oncology · 33
Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial
2022 · Eric François, Berardino De Bari, et al. · European Journal of Cancer · 27
PDF
NACRE: A randomized study comparing short course radiotherapy with radiochemotherapy for locally advanced rectal cancers in the elderly—Preliminary results.
2021 · Eric FRANCOIS, Mandy Pernot, et al. · Journal of Clinical Oncology · 25
Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE
2023 · Véronique VENDRELY, Claire LEMANSKI, et al. · Radiotherapy and Oncology · 22
PDF
Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1 trial.
2023 · Loic Mourey, Helen Jane Boyle, et al. · Journal of Clinical Oncology · 22
PDF
1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial
2022 · G. Gravis Mescam, X. Maldonado, et al. · Annals of Oncology · 17
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial
2025 · Guilhem Roubaud, Marie Kostine, et al. · European Journal of Cancer · 15
PDF
MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma
2021 · Nicolas Giraud, Olivier Saut, et al. · Cancers · 14
PDF
Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessment
2024 · Eric François, Nicolas Magné, et al. · Radiotherapy and Oncology · 11
PDF
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol
2023 · Maximilien Rogé, Yoann Pointreau, et al. · Clinical and Translational Radiation Oncology · 11
Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial
2023 · Véronique Vendrely, Philippe Ronchin, et al. · Radiotherapy and Oncology · 10
PDF
What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort
2021 · Manon Bacci, Laurent Quero, et al. · Digestive and Liver Disease · 9
PDF
The acute toxicity results of the GETUG-AFU 22 study: A multicenter randomized phase II trial comparing the efficacy of a short hormone therapy in combination with radiotherapy to radiotherapy alone as a salvage treatment for patients with detectable PSA after radical prostatectomy.
2017 · Stephane Gilles Guerif, Igor Latorzeff, et al. · Journal of Clinical Oncology · 9
Works count: 73
Citation count: 4,695
H-index: 18
I10-index: 24
Year
Topic
Type